Interaction Patterns of Pyrazolopyrimidines with Receptor Proteins

Area of Science:

• Medicinal Chemistry
• Structural Biology
• Computational Chemistry

Background:

• Heterocyclic compounds, particularly pyrazolopyrimidines, are vital scaffolds in medicinal chemistry and drug discovery.
• These nitrogen heterocycles are present in numerous biologically active compounds and marketed drugs.
• Understanding their interactions with biological targets is crucial for rational drug design.

Purpose of the Study:

• To investigate the non-covalent interactions between pyrazolopyrimidine ligands and receptor proteins.
• To analyze high-resolution crystal structure data from the Protein Data Bank (PDB).
• To provide geometric parameters for pyrazolopyrimidine-protein interactions to aid in silico modeling.

Main Methods:

• Data mining of the Protein Data Bank (PDB) for crystal structures containing pyrazolopyrimidine derivatives.
• Analysis of 471 crystal structures to identify ligand types (Pyp1, Pyp2, Pyp3, Pyp4) and receptor protein families.
• Detailed examination of non-covalent interactions, including hydrogen bonds and aromatic π···π interactions, and measurement of centroid-centroid distances.

Main Results:

• Pyrazolopyrimidine derivatives were found in 471 PDB structures, with 1H-pyrazolo[3,4-d]pyrimidines (Pyp1) being the most common (50%).
• Transferases were the most frequent receptor protein class (67.5%), followed by hydrolases and oxidoreductases.
• Aromatic π···π interactions (∼91%) and hydrogen bonds/polar contacts (∼73%) were the dominant interactions, with an average centroid-centroid distance of 5.32 Å for high-resolution structures (<2.0 Å).

Conclusions:

• Pyrazolopyrimidines engage in significant aromatic and polar interactions with receptor proteins, primarily transferases.
• The prevalence of specific pyrazolopyrimidine isomers and interaction types provides valuable insights into their binding modes.
• Geometric data on these interactions can enhance the accuracy and efficiency of future in silico drug design and modeling studies involving pyrazolopyrimidines.